Literature DB >> 17962638

Molecular predictive factors for progression of high-grade preinvasive bronchial lesions.

Mathieu Salaün1, Richard Sesboüé, Sophie Moreno-Swirc, Josette Metayer, Suzanna Bota, Jeannette Bourguignon, Luc Thiberville.   

Abstract

RATIONALE: The outcome of precancerous bronchial lesions is not well known, and their management is subject to controversy. Many molecular alterations are present in preinvasive lesions, but none has been assessed to predict the evolution of the lesions.
OBJECTIVES: To analyze the outcome of high-grade precancerous lesions according to their molecular profile.
METHODS: Twenty-three severe dysplasia and 31 carcinoma in situ (CIS) lesions in 37 patients were monitored using repeated autofluorescence bronchoscopy over a 12-year period. Microdissection and polymerase chain reaction analysis were performed on paraffin tissue sections to assess loss of heterozygosity (LOH) and microsatellite instability on chromosome 3p, 5q, and 9p. Histology and molecular status at baseline were compared between 7 lesions that became invasive, 11 that relapsed after treatment, 17 that were eradicated with local treatment, and 19 that spontaneously regressed.
MEASUREMENTS AND MAIN RESULTS: Ninety-four percent of lesions that progressed or relapsed were CIS at baseline, whereas 79% of spontaneously regressing lesions were severe dysplasia (P < 0.0001). 3p and 9p LOH was more frequent in CIS than in severe dysplasia (P = 0.03). In the whole group of lesions as well as in the CIS group, 3p LOH was strongly associated with progression (P < 0.0001 and P = 0.02, respectively). Microsatellite instability was not associated with the outcome of the lesions. A therapeutic strategy based on the presence of 3p or 9p LOH would have led to overtreatment of six lesions but would have missed only 1 among the 18 progressing lesions.
CONCLUSIONS: Baseline histology and 3p LOH analysis appear to be useful in predicting the outcome of high-grade precancerous lesions.

Entities:  

Mesh:

Year:  2007        PMID: 17962638     DOI: 10.1164/rccm.200704-598OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  15 in total

1.  Oral iloprost improves endobronchial dysplasia in former smokers.

Authors:  Robert L Keith; Patrick J Blatchford; John Kittelson; John D Minna; Karen Kelly; Pierre P Massion; Wilbur A Franklin; Jenny Mao; David O Wilson; Daniel T Merrick; Fred R Hirsch; Timothy C Kennedy; Paul A Bunn; Mark W Geraci; York E Miller
Journal:  Cancer Prev Res (Phila)       Date:  2011-06

2.  Progressive endobronchial premalignancy: marked by original CIN.

Authors:  Christopher D Coldren; York E Miller
Journal:  Am J Respir Crit Care Med       Date:  2011-10-15       Impact factor: 21.405

3.  Preinvasive Endobronchial Lesions: Lung Cancer Precursors and Risk Markers?

Authors:  Stephen Lam; Eva Szabo
Journal:  Am J Respir Crit Care Med       Date:  2015-12-15       Impact factor: 21.405

Review 4.  Update in lung cancer 2008.

Authors:  Sarita Dubey; Charles A Powell
Journal:  Am J Respir Crit Care Med       Date:  2009-05-15       Impact factor: 21.405

Review 5.  [Preneoplastic lesions of pulmonary carcinoma].

Authors:  L Bubendorf
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

Review 6.  Natural history of bronchial preinvasive lesions.

Authors:  Taichiro Ishizumi; Annette McWilliams; Calum MacAulay; Adi Gazdar; Stephen Lam
Journal:  Cancer Metastasis Rev       Date:  2010-03       Impact factor: 9.264

7.  Detection and minimally invasive treatment of early squamous lung cancer.

Authors:  Johannes M A Daniels; Thomas G Sutedja
Journal:  Ther Adv Med Oncol       Date:  2013-07       Impact factor: 8.168

Review 8.  The technique of endoscopic airway tumor treatment.

Authors:  Simone Scarlata; Lello Fuso; Gabriele Lucantoni; Francesco Varone; Daniele Magnini; Raffaele Antonelli Incalzi; Gianni Galluccio
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

9.  [What's new in lung pathology: minutes from the Pulmonary Pathology Working Group of the German Society of Pathology].

Authors:  I Petersen; P A Schnabel
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

Review 10.  Lung cancer chemoprevention: current status and future prospects.

Authors:  Robert L Keith; York E Miller
Journal:  Nat Rev Clin Oncol       Date:  2013-05-21       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.